ProShares Bitcoin ETF vs Nuwellis Inc — how do they compare? ProShares Bitcoin ETF trades at $8.86, while Nuwellis Inc trades at $3.2 (market cap $1.17M). Which is the better fit depends on your goals.
| BITO | NUWE | |
|---|---|---|
Sector | Crypto-linked | Technology |
52-Week High | $22.93 | $558.26 |
52-Week Low | $7.98 | $2.80 |
Market Cap | — | $1.17M |
Enterprise Value | — | -$636.97K |
Signals from Pluang's Aura AI — not financial advice
BITO trades at $8.44, down 2.65% today amid bearish technical signals with 12 sell indicators versus 4 buy signals. The ETF faces challenges with declining distributions and negative sentiment as crypto markets struggle. Recent dividend payments of $0.01-$0.02 per share provide limited offset to the fund's 24.26% five-year decline.
The outlook remains cautious with structural costs and Bitcoin correlation concerns weighing on performance. Key risks include management fee drag, distribution volatility, and crypto market exposure. Investors should monitor fee structure efficiency and Bitcoin market stability for potential recovery catalysts.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Trailing returns across standard periods
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →